APR 20, 2017 10:00 AM SGT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
WEBINAR: Patient Derived Micro Tumor systems: Future Trends towards improved testing systems
SPONSORED BY: PerkinElmer
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: P.A.C.E. CE | Florida CE
3 3 387

Speakers:
  • Platform Leader - Centre for High Throughput Phenomics, Genome Institute of Singapore
    Biography
      Dr. Giridharan Periyasamy is a Platform Leader of Centre for High Throughput Phenomics (CHiP-GIS) at the Genome institute of Singapore. His research focus is on the Cancer biology, Drug resistance, Disease modeling and signaling pathway networks of human diseases. In his core, he has potential to run high throughput functional and chemical genomics for target identification/ validation and proof of principle studies.

      His current focus is on discovery/identification of novel gene function(s) and phenotypes upon RNAi-mediated gene silencing or cDNA over expression for uncovering novel mechanisms of drug resistance. He is also intend to develop robust and comprehensive panel of 3D cell culture models patient derived primary cells for the characterization of different disease phenotypes, and investigate chemo-response to novel or known drugs. Furthermore he would like to establish array of next generation preclinical 3D tissue models for predictive toxicology screening and validation against traditional animal model systems.

      Prior to his current position, he worked as a Scientific Director of HTS/HCS Screening Core Facility at C-CAMP, NCBS, India and a Group Leader at Piramal Life Sciences Ltd in Mumbai India. Dr.Giri studied in Centre for Biotechnology at Anna University where he obtained his Ph.D. in Biotechnology, and he has more than 15 significant publications and 8 patents to his credit.

    Abstract:

    DATE: April 20th, 2017
    TIME: 10:00AM SGT, 11:00AM KST, 12:00PM AEST, 2:00PM NZST

    With increasing breadth and depth of genomics studies across a range of cancers, it is now apparent that there exists significant inter and intra tumoural heterogeneity, with complex genotypes comprising of multiple co-existing genetic and epigenetic alterations. Current efforts at genomic characterization of individual cancers however, has several limitations: A significant proportion of patients invariably develop resistance to current targeted therapies, for which the mechanisms are not fully unraveled, and there remain a paucity of treatment options. More than 1 genomic alteration may co-exist, and the effect of co-mutations can be unpredictable from a target modulation perspective.

    In this project, we plan to propagate patient derived cell lines in order to allow functional studies that may expand therapeutic opportunities beyond genomic-based markers. Functional studies comprise both chemical and genetic tools that perturb the signaling networks in the primary cell cultures, in order to unravel complex signaling networks that interact through crosstalk and feedback loops, which modify therapeutic vulnerability. Such screens can therefore provide insights into mediators of resistance and sensitivities, yielding predictive biomarkers as well as novel drug combinations to circumvent drug resistance.

    Two crucial components include an efficient scalable system to explore therapeutic combinations and the development of representative preclinical models: Patient-derived cells in 3D culture models reflect an integration of genetic, epigenetic, and environmental influences, and may closely mimic the chemotherapeutic (or pathway specific inhibitor)-response of the actual tumor in patients. Thus we aim to exploit the relevance and scalability of patient-derived cell lines to perform HTS/HCS based screens.

    Learning Objectives:

    • Cancer heterogeneity and resistance 
    • Power of High content screening in disease biology 
    • 3D cell culture models and importance

     


    Show Resources
    Loading Comments...